Comparative effectiveness research can help set fairer drug prices, paper says

17 March 2023
drug_money_man_stock_large

The Institute for Clinical and Economic Review (ICER) is continuing to play a lead role in debate over drug prices in the USA.

The ICER has published a white paper called Applying the Results of Comparative Effectiveness Research to Control Drug Costs: Policy Options for California.

The paper details how comparative effectiveness research can be used by policymakers and health insurers in California to address rising drug costs by aligning spending with the degree of benefit a treatment provides.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical